Liver-targeted chemo may boost survival in bile duct cancer
NCT ID NCT07304388
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This study tested whether adding a liver-directed chemotherapy infusion (HAIC) to a standard drug combo (Gemox, lenvatinib, toripalimab) helps people with advanced bile duct cancer live longer without the disease getting worse. 96 patients took part. The goal was to see if the extra treatment improves 6-month progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Center Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, oxaliplatin, lenvatinib, toripalimab
What this could lead to
If adding liver-directed chemo works, it could offer a new option to control advanced bile duct cancer and extend life.
What could go wrong
This is a small phase 2 trial, so results may not be definitive. Adding more chemo could increase side effects without clear benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.